Pfizer Deal With pSivida Could Lead To Ophthalmic Drug Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Australian firm gives Pfizer access to novel, controlled-release drug delivery technology.
You may also be interested in...
Merck Obtains Access To SurModics’ Ophthalmic Drug Delivery System In Potential $300 Million Deal
I-vation system is currently being studied in combination with triamcinolone acetonide for treatment of diabetic macular edema.
Merck Obtains Access To SurModics’ Ophthalmic Drug Delivery System In Potential $300 Million Deal
I-vation system is currently being studied in combination with triamcinolone acetonide for treatment of diabetic macular edema.
Pfizer Revs Acquisition Engine; New Management Has $17 Bil. To Spend On Deals
Pfizer signs licensing agreement with Quark Biotech to develop a novel human gene for treatment of wet age-related macular degeneration.